Introduction
============

Age-related macular degeneration (AMD) is an ophthalmic disease that is characterized by early subclinical changes in choroidal and retinal pigment epithelium. The rationale for progression of AMD leading to "geographic atrophy" or "choroidal neovascularization" remains enigmatic. Knowledge of the pathogenesis and causal factors of the disease is therefore needed. AMD appears to be a devastating disease because of the dramatic loss of the central visual field that ultimately affects quality of life \[[@r1]\].

Being a normal process of life, aging acts as a major determinant of AMD; however several other factors, including oxidative stress and a genetic tendency, also contribute toward the pathogenesis of AMD \[[@r2]\]. Pathologically, AMD is considered to be an inflammatory disease \[[@r3]\] because as the disease progresses, macrophages and giant cells accumulate near the drusen, subretinal neovascular membrane, and Bruch's membrane. Microglial cells then get involved in the inflammatory process; they support the phagocytosis of debris by secreting chemokines and cytokines to create neurotoxic milieu, all resulting in the progression of AMD pathogenesis \[[@r4]\].

The single nucleotide polymorphism (SNP) of many inflammatory factors has been studied in AMD patients. These include toll-like receptor 3, complement factor H, CX3C chemokine receptor 1 (CX3CR1), and interleukin 8 (IL-8) \[[@r4]\]. The variation in cytokine production at the individual level is influenced by genetic polymorphism in the respective gene(s). Consequently, it becomes difficult to consider that AMD is a single-gene disorder. Since the genes associated with AMD show a high degree of variability and interference \[[@r5]\], it seems logical to investigate these variations and determine the role of inflammatory factors in the pathology of AMD. IL-8, which is a member of the chemokine family, is a multifunctional cytokine and is involved in both chronic and acute inflammation \[[@r6]\]. Due to its pro-angiogenic properties, IL-8 appears to be involved in choroidal neovascularization (CNV), a clinical and pathologic complication associated with AMD. It has been shown that new blood vessels that grow during AMD express both VEGF and IL-8 \[[@r7]\]. IL-6 is another cytokine with numerous functions ranging from regulation of the immune response to acute-phase reactions and hematopoiesis \[[@r8]\]. Under normal healthy conditions, the balance between anti-angiogenic and angiogenic growth factors prevents the growth of anomalous blood vessels, but CNV arises as soon as an imbalance occurs between the two \[[@r9]\].

Reduced oxygen levels in the retina stimulate VEGF production in many cell types, including endothelial cells, Muller cells, RPE cells, and pericytes \[[@r10]\]. Elevated VEGF levels in the retina promote neovascularization \[[@r11]\], whereas an inhibition of VEGF downregulates CNV \[[@r12]\]. Bhutto et al. \[[@r13]\] showed that in eyes affected with AMD, VEGF levels are elevated in the posterior segment before CNV occurs, but the exact mechanism of VEGF release/stimulation in CNV is not clear.

C-reactive protein (CRP), which is another inflammatory marker, is a known risk factor for cardiovascular and peripheral arterial disease \[[@r14],[@r15]\]. Hypertension and diabetes mellitus are systemic disorders that increase the risk of vascular abnormalities in the retina. Inflammation and endothelial cell dysfunction are therefore suggested to play significant roles in the development of retinopathy \[[@r16]\]. Increased levels of CRP in the serum greatly increase the risk of inflammatory disorders \[[@r17]\]. Studies on aged African Blacks and young White populations showed that plasma CRP levels are related to genetic make-up \[[@r18],[@r19]\]. In this context, the CRP gene haplotype strongly influences plasma CRP levels in an individual \[[@r20],[@r21]\], and alleles associated with elevated plasma CRP levels may confer an increased risk of AMD.

We hypothesized that gene polymorphism is an important determinant in the pathogenesis of AMD. The aims of the current study were to determine the levels of IL-6, IL-8, VEGF, and CRP in the sera of AMD patients and to investigate their association with the SNPs of respective genes. Using the standard restriction fragment length polymorphism (RFLP) technique, we analyzed three SNPs of interleukins genes: IL-6 ([rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795), [rs1800796](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800796), [rs1800797](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800797)) and IL-8 ([rs4073](http://www.ncbi.nlm.nih.gov/snp/?term=rs4073), [rs2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306), [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543)); and two SNPs of VEGF genes: ([rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947)) and CRP [(rs1205](http://www.ncbi.nlm.nih.gov/snp/?term=rs1205), [rs113086](http://www.ncbi.nlm.nih.gov/snp/?term=rs113086)).

Methods
=======

Ethics
------

The study conformed to the tenets of the Declaration of Helsinki \[[@r22]\] and was formally approved by the Bioethics Committee of Quaid-i-Azam University, Islamabad, Pakistan (Protocol\# BEC-FBS-QAU-06) and the Ethics Committee of Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan. Written informed consent was obtained from each subject after narrating the study procedures.

Study design and subjects
-------------------------

This was a cross-sectional and case-control study. Detailed proformas were designed to record anthropometric parameters and the clinical history of the disease. A total of 3,911 patients who presented for ophthalmic complications at the Al-Shifa Trust Eye Hospital over a period of about 1 year were screened, and the presence of AMD was diagnosed after slit-lamp examination (C-153 Topcon SL-3D; Santa Clara, CA), ocular coherence tomography (OCT; Zeiss, Oberkochen, Germany), and fluorescent fundus (FFA) done through retinal camera TRC50EX using digital imaging system, IMAGEnet 2000, (Topcon). Inclusion criteria for patients were subjects of both genders aged ≥50 years, nondiabetic, and normotensive with no complication(s) of the eye other than AMD. Subjects with arthritis, diabetes, cancer, end-stage renal disease, arteriosclerosis, and/or using antimetabolite or anti-inflammatory therapy were excluded from the study. Consequently, only 59 males and 31 females who fulfilled the inclusion criteria were selected to participate. Control subjects met the same inclusion criteria and underwent detailed examination for confirmation of healthy ocular conditions. The identity of the healthy subjects and AMD patients was confirmed during the interviews and through certificates of residence as to whether they were Pakistanis by birth. Patients and subjects whose identity as Pakistanis could not be confirmed were omitted from the study.

Blood sampling
--------------

Cubital blood (6 ml) was collected for estimation of serum IL-6, IL-8, VEGF, CRP levels, and DNA extraction. We collected blood samples in gel tubes, prepared the sera, and stored them at −20 °C. To avoid long-term storage, serum samples were analyzed after every 20 samples.

Determination of IL-6, IL-8, VEGF, and CRP Levels
-------------------------------------------------

Commercially available ELISA kits were used for the estimation of IL-6 and IL-8 (Immunotech, Marseille Cedex, France), VEGF (Cusabio, Wuhan, Hubei, China), and CRP (Amgenix, San Jose, CA). Analyses were performed in triplicate on a fully automated microplate reader with washer (KHB-ST 360; Shanghai, China) following the manufacturer's instructions. Briefly, for IL-6, 100 µl of standard and serum samples were added to the wells of a 96-well plate precoated with monoclonal antibody. After incubation for 2 h at 18-25 °C, the plate was washed thoroughly with washing solution (PBS + 0.05% Tween 20) and 200 µl of enzyme-conjugated horse reddish protein (HRP) streptavidin substrate was added. The plate was incubated for 30 min in dark at 18-25 °C, after which stop solution (2M H~2~SO~4~) was added and optical density (OD) was recorded on an ELISA plate reader at 405 nm wavelength. A standard curve was plotted from the ODs observed for the standard solutions (0.00--1000 pg/ml), and the concentration of IL-6 was calculated from the standard curve. The analytic range for the IL-6 ELISA kit was 3 pg/ml to 150 ng/ml. The intra-assay coefficient of variation (CV) ranged between 1.6% and 6.8%; the inter-assay CV ranged between 7.9% and 14.6%.

For estimation of serum IL-8, 150 µl of standard or sample was added per well and incubated for 2 h at 18--25 °C while shaking. After thoroughly washing the plate, 50 μl of biotinylated antibody and 100 μl of streptavidin-horseradish peroxidase (HRP) conjugate were added and incubated for 30 min at 18--25 °C. Then, 50 μl of stop solution was added, and absorbance was recorded at 450 nm by an ELISA plate reader. A standard curve was plotted from the ODs observed for the standard solutions (0.00--2000 pg/ml), and the concentration of IL-8 was calculated from the standard curve. The kit was sensitive to measure 8 pg/ml. Intra-assay CV ranged between 2.3% and 5.5%, whereas inter-assay CV ranged between 7.6% and 10.1%.

For the measurement of serum VEGF levels, samples were diluted 1:2 with distilled water and 100 μl of standard or diluted samples was added to the wells of precoated plate. Samples were incubated for 2 h at 37 °C, after which the contents were removed. Then, 100 µl of biotin antibody solution was added, and the plate was incubated for 1 h at 37 °C. The plate was then washed thoroughly, and 100 μl of HRP-avidin solution was added. Samples in the plate were incubated again for 1 h at 37 °C and followed by another washing. Ninety microliters of tetramethylbenzidine (TMB) solution was added and incubated for about 15--30 min at 37 °C; 50 μl stop solution (2M H~2~SO~4~) was then added to each well. Absorbance was recorded immediately on a microplate reader at 450 nm and 570 nm. The reading at 570 nm was subtracted from the 450-nm reading, and a standard curve was plotted from the readings of the standards. VEGF concentration was calculated through interpolation of the calibration curve. The unknown concentration in the serum samples was calculated from the standard curve and multiplied by the dilution factor. The detection range of the kit was 31.25--2000 pg/ml. The intra-assay CV was \<8%, while the inter-assay CV was \<10%.

For the estimation of CRP serum concentration, samples were diluted to 1:100 with distilled water. To each well of the plate, 50 µl of standard or sample was added, followed by 50 µl of high sensitivity C - reactive protein (hsCRP) sample diluents. The plate was shaken thoroughly for 30 min and washed thoroughly. Then, 100 µl of CRP enzyme conjugate reagent was added to each well, mixed thoroughly for 30 s, and incubated for 30 min. The plate was washed again, and 100 µl of TMB reagent was added to each well and mixed for about 5 s. Incubation at 18-22 °C was performed for 30 min, after which a stop solution (2M H2SO4) was added that changed the color from blue to yellow. Absorbance was recorded at 450 nm as above. A standard curve was plotted, and the concentration was calculated by multiplying the obtained value by the dilution factor. The detectable range was 1--100 ng/ml. The intra-assay CV ranged between 3.68% and7.67% CV, while the inter-assay CV ranged between 6.04% and 9.82%.

DNA extraction
--------------

For DNA extraction, cubital blood was collected in tubes containing potassium ethylene diamine tetra acetic acid (K^3^.EDTA) (Becton Dickinson and Company, BD, Franklin Lakes, NJ). Whole blood genomic DNA extraction was performed by using the standard organic method of DNA extraction \[[@r23]\]. PCRs were run using the specific primer sets designed for each SNP: IL-6 ([rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795), [rs1800796](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800796), [rs1800797](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800797)); IL-8 ([rs4073](http://www.ncbi.nlm.nih.gov/snp/?term=rs4073), [rs2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306), [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543)); VEGF ([rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039), [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947)); and CRP ([rs1205](http://www.ncbi.nlm.nih.gov/snp/?term=rs1205), [rs113086](http://www.ncbi.nlm.nih.gov/snp/?term=rs113086); [Table 1](#t1){ref-type="table"}).

###### Primer sequence and PCR optimization conditions with restriction enzymes.

  **Gene variants**                         **rs number**   **Primer sequence**                      **uncut**   **cut**   **Restriction enzymes**   **Annealing temperature (˚C)**
  ----------------------------------------- --------------- ---------------------------------------- ----------- --------- ------------------------- --------------------------------
  IL-6 174 G \> C                           1800795         Forward: 5\' TGACTTCAGCTTTACTCTTTGT3\'   198         G: 198    *Sfa*N1                   56.0
  Reverse: 5\'CTGATTGGAAACCTTATTAAG3\'      C:144                                                                                                    
  IL-6 572 C \> G                           1800796         Forward: 5\'GCAAAGTCCTCACTGGGAGGA3\'     296         C: 296    *Bsr*B1                   64.0
  Reverse: 5\'TCTGACTCCATCGCAGCCC3\'        G: 202                                                                                                   
  IL-6 597 A \> G                           1800797         Forward: 5\'GGAGTCACACACTCCACCTG3\'      419         G: 419    *Fok*1                    64.0
  Reverse: 5\'AGCAGAACCACTCTTCCTTTACTT3\'   A: 362                                                                                                   
  IL-8 251 A \> T                           4073            Forward: 5′TCATCCATGATCTTGTTCTAA3\'      542         T: 542    *Mfe*1                    60.0
  Reverse: 5′GGAAAACGCTGTAGGTCAGA3\'        A: 449                                                                                                   
  IL-8 781 C \> T                           2227306         Forward: 5′CTCTAACTCTTTATATAGGAATT3\'    203         T: 203    *Eco*R1                   56.0
  Reverse: 5′GATTGATTTTATCAACAGGCA3\'       C: 185                                                                                                   
  IL-8 1633 C \> T                          2227543         Forward: 5′CTGATGGAAGAGAGCTCTGT3\'       397         T: 397    *Nla*III                  60.0
  Reverse: 5′TGTTAGAAATGCTCTATATTCTC3\'     C: 233                                                                                                   
  VEGF 936 C \> T                           3025039         Forward 5ꞌ AAGGAAGAGGAGACTCTGCGC3ꞌ       198         T:198     *Hpy*CH4 III              58.0
  Reverse 5ꞌ TATGTGGGTGGGTGTGTCTACAG3ꞌ      C:112                                                                                                    
  VEGF 2578 A \> C                          699947          Forward 5ꞌ GGATGGGGCTGACTAGGTAAGC3ꞌ      324         *C:324*   *Bg*lII                   55 .0
  Reverse 5ꞌ AGCCCCCTTTTCCTCCAAC3ꞌ          A:202                                                                                                    
  CRP 1846 C \> T                           1205            Forward 5ꞌ GGAGTGAGACATCTTCTTG3ꞌ         227         *A:227*   *Hpy*CH4 III              50.0
  Reverse 5ꞌ CTTATAGACCTGGGCAGT3ꞌ           G:131                                                                                                    
  CRP 1444 G \> A                           1130864         Forward 5ꞌ AGCTCGTTAACTATGCTGGG3ꞌ        181         *C:181*   *Hpy*CH4 III              59.0
  Reverse 5ꞌ CTTCTCAGCTCTTGCCTTAT3ꞌ         T:156                                                                                                    

PCR and restriction fragment length polymorphism (RFLP)
-------------------------------------------------------

Unless otherwise indicated, all reagents were obtained from Invitrogen (Paisley, UK). For each sample, PCR was performed with a final volume of 20 μl. This mixture contained 40 ng genomic DNA, 2 μl of PCR buffer without Mg^2+^, 1 μl of 25 mM MgCl~2~, 0.2 μl (5 U/μl) Taq DNA polymerase, 1 μl of 2 mM dNTPs, and 1 μl each of 20 nM forward and reverse primers (e-oligos, Gene Link, Inc, New York, NY). The final volume was adjusted to 20 μl with PCR-grade water.

PCR was performed in a thermal cycler (Thermo electron Corporation, Millford). PCR conditions were the following: denaturation at 94 °C for 5 min with 1 cycle, denaturation at 94 °C for 45 s, annealing for 45 s at the temperature specific for each primer set ([Table 1](#t1){ref-type="table"}), and extension at 72 °C for 1 min. The number of cycles at step 2 was 35. In step 3, the final extension was performed at 72 °C for 10 min. The PCR product was mixed with 5 U of restriction enzyme and the reaction buffer as per the manufacturer's instructions. The cuttable and uncuttable products are shown in [Table 1](#t1){ref-type="table"}. The mixture was incubated for 16--18 h at 37 °C and, 5 μl of product after the enzyme reaction was loaded onto 3% agarose gel containing ethidium bromide. A 100-bp DNA ladder (Invitrogen) was run alongside to compare the sizes of fragments.

DNA sequencing
--------------

Sequencing was carried out through the standard method of Sanger DNA sequencing. For each SNP, purified PCR products were loaded onto an ABI 3130 genetic analyzer, 3013 (Applied Biosystems, Life Technology, Thermo electron Corporation, Millford, CA). The results of sequencing were read, and the SNP genotypes were validated.

Statistical analysis
--------------------

Data were transformed using XLSTAT (version 2015, Belmont, MA). Statistical analyses were performed with Statistical Product and Service Solutions (SPSS) software (version 18.0; IBM, Chicago, IL), and graphs were drawn using GraphPad Prism software (GraphPad Prism Version 5.00 for Windows; San Diego, CA). The data were transformed using the method described by Box and Cox \[[@r24]\] for reducing heterogeneity of error that permitted the assumption of equal variance to be met. The data were transformed using the method as described by Box and Cox for reducing heterogeneity of error that permitted the assumption of equal variance to be met. Box and Cox transformation provided an algorithm through which the optimal value of the transformation parameter λ was selected by the method of maximum likelihood. Transformed data were subjected to multivariate analysis of variance (M-ANOVA) for statistical evaluation of the association of serum IL-6, IL-8, CRP, and VEGF levels with AMD and gender of the subject. One-way ANOVA was applied to evaluate the association of heterozygosity and homozygosity of studied SNPs with the serum levels of each protein. The expected Hardy--Weinberg frequencies for the alleles and genotypes were calculated, and any deviation of data from Hardy--Weinberg equilibrium was tested through χ^2^ analysis. For each SNP, allele frequencies are given in the results section. The probability value was p\<0.05.

Results
=======

Anthropomorphic history and diagnostics
---------------------------------------

Diagnostic symptoms for AMD included small or large drusen, sub retinal CNV, hemorrhages, edema, geographic atrophy and RPE atrophy. Of the AMD patients, 65.5% were males and 34.5% were females. Of the 100 control subjects, 55 were males and were 45 females. There was no significant difference as regards age in any of the groups (p\<0.448). Diagnostic characteristics of the AMD patients are presented in [Table 2](#t2){ref-type="table"}.

###### Number of subjects, age, gender and diagnostic parameters in control subjects and AMD patients.

  **Characteristics**   **Control**   **AMD**
  --------------------- ------------- -------------
  N                     100           90
  Males                 55            63
  Females               45            27
  Age (median ± SE)     63.0 ± 0.84   70.0 ± 1.07
  Wet AMD               NA            59
  Dry AMD               NA            31
  Maculopathy Pattern   NA            32
  Exudative Pattern     NA            40
  Atrophic Pattern      NA            18

NA: not applicable

Serum levels of IL-6, IL-8, VEGF and CRP
----------------------------------------

The ANOVA for λ= 0.413 that yielded the lowest error sums of squares was used for hypothesis testing. M-ANOVA showed that serum levels of IL-6, IL-8, VEGF and CRP were significantly elevated in AMD patients (p\<0.0001; Wilk's λ = 0.064; F= 278.7); however, these levels were not found to be associated with gender (p\<0.560; Wilk's λ = 0.997; F= 0.463). The levels of all these factors were found significantly associated with the type of AMD that is wet or dry (p\<0.0001; Wilk's λ = 0.018; F= 147.406). IL-6 and IL-8 levels were significantly increased in patients with dry AMD (p\<0.0001), while serum VEGF and CRP levels were significantly elevated in patients with wet AMD (p\<0.0001; [Figure 1A-D](#f1){ref-type="fig"}). There was no significant difference in the serum levels of inflammatory factors with respect to age groups (p\>0.705; Wilk's λ = 0.983; F=0.631; [Table 3](#t3){ref-type="table"}). No significant change was observed in the concentration of IL-6, IL-8, VEGF, and CRP with respect to the pattern of AMD (p\<0.302; Wilk's λ = 0.882; F=1.202; [Table 4](#t4){ref-type="table"}).

![The box-and-whisker plot represents the mean and minimum to maximum range of IL-6, IL-8, VEGF and CRP levels in transformed data. Serum levels were measured in 100 control subjects and 90 AMD patients. Among AMD patients 63 had wet type and 27 had dry type AMD. The serum levels of (**A**) IL-6, (**B**) IL-8, (**C**) VEGF and (D) CRP were significantly elevated in AMD patients compared to control subjects (p\<0.0001). The levels of (**A**) IL-6 and (**B**) IL-8 were significantly elevated in dry AMD patients compared to wet AMD patients. The levels of (**C**) VEGF and (**D**) CRP were significantly elevated in wet AMD patients compared to dry AMD patients (p\<0.0001).](mv-v21-985-f1){#f1}

###### Comparison of levels of IL-6 (pg/ml), IL-8 (pg/ml), VEGF (pg/ml) and CRP (ng/ml) with respect to each age group.

  **Age group**   **Group**   **N**   **IL-6**     **IL-8**     **VEGF**     **CRP**
  --------------- ----------- ------- ------------ ------------ ------------ ------------
  50-59           Control     45      8.55±0.37    13.03±0.15   16.96±0.57   4.042±0.75
                  AMD         15      11.18±0.80   12.82±0.22   19.38±0.63   1.646±0.32
  60-69           Control     30      10.10±0.39   12.69±1.11   16.82±0.69   4.91±0.99
                  AMD         33      9.73±0.45    13.61±0.21   17.35±3.87   4.34±0.82
  70-79           Control     21      9.117±0.48   12.38±0.22   19.18±0.56   1.947±0.77
                  AMD         29      10.54±0.43   13.31±0.18   19.14±0.51   3.62±0.61
  80-89           Control     4       9.866±1.24   12.65±0.57   18.07±1.90   4.25±2.75
                  AMD         10      9.51±0.89    13.50±0.26   17.45±1.22   4.79±1.27
  90-99           Control     0       none         none         none         none
                  AMD         2       17.72±5.35   14.62±1.60   16.24±3.87   -0.15±0.34
  ≥100            Control     0       none         none         none         none
                  AMD         1       12.346       12.37        22.46        2.797

none: means no subject in these age groups could be found in the control group

###### Levels of IL-6 (pg/ml), IL-8 (pg/ml), VEGF (pg/ml) and CRP (ng/ml) with respect to pattern of AMD.

  **Protein**   **N**   **IL-6**     **IL-8**     **VEGF**     **CRP**
  ------------- ------- ------------ ------------ ------------ -----------
  Maculopathy   32      11.71±0.94   13.73±0.81   17.03±0.97   3.90±0.91
  Exudative     40      9.83±0.40    13.30±0.56   18.81±0.54   4.26±0.62
  Atrophic      18      10.94±0.47   12.94±0.59   18.79±0.60   2.83±0.61
  p Value       \-      0.058        0.284        0.249        0.280

Allele and genotype frequencies of IL-6
---------------------------------------

Among SNPs of IL-6, the frequency of the CC genotype for SNP [rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795) (p\<0.002; odds ratio \[OR\] = 0.4981; confidence interval \[CI\] 0.2422 -- 1.0243) was significantly increased compared to other genotypes. The frequency of allele C increased significantly (p\<0.0001; OR= 3.7096; CI 2.2357 -- 6.1551) in AMD patients compared to control subjects. For SNP [rs1800796](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800796), the difference in genotype frequency between the control subjects and AMD patients was not significant (p\<0.7958; OR= 1.7024; CI 0.9555 -- 3.033). There was no significant difference in the allele frequency between control group and AMD patients (p\<0.8957; OR = 1.0279; CI 0.6829 -- 1.5472). When SNP [rs1800797](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800797) was compared to other genotypes, the frequency of genotype GA was significantly reduced (p\<0.0001; OR= 0.1499; CI 0.0626-0.3588). Furthermore, the frequency of allele A was significantly reduced (p\<0.0001; OR= 0.1843; CI 0.0798-0.4258) in AMD patients when compared with healthy controls. The serum concentration of IL-6 was significantly higher in AMD patients with genotype GG compared to those with genotypes GC or CC for SNP [rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795) (p\<0.0001; F= 8.801). No significant change was observed in serum IL-6 concentration with respect to genotype in other SNPs of IL-6 ([Table 5](#t5){ref-type="table"}).

###### Genotype and allele frequencies in control and AMD patients for IL-6 SNPs**.**

  **Genotype**    **t test**       **Control (N=100)**   **AMD (N=90)**   **Alleles**      **Allele frequency reported in Pakistan (%)** \[[@r25]\]   **Control**   **AMD**   **p value**                     
  --------------- ---------------- --------------------- ---------------- ---------------- ---------------------------------------------------------- ------------- --------- --------------- --------------- ----------------
  rs**1800795**                                                                                                                                                                                               
  GG              0.0001^\*\*\*^   0.105                 2.707            0.0001^\*\*\*^   8.801                                                      G             87        0.865 (86.5%)   0.633 (63.3%)   0.0001^\*\*\*^
  GC              0.916            C                     13               0.135 (13.5%)    0.367 (36.7%)                                                                                                      
  CC              NA                                                                                                                                                                                          
  **rs1800796**                                                                                                                                                                                               
  GG              0.010^\*^        0.514                 0.671            0.293            1.254                                                      G             67        0.59 (59%)      0.583 (58.3%)   0.896
  GC              0.0001^\*\*\*^   C                     33               0.41 (41%)       0.417 (41.7%)                                                                                                      
  CC              0.044^\*^                                                                                                                                                                                   
  **rs1800797**                                                                                                                                                                                               
  GG              0.0001^\*\*\*^   3.154                 0.081            0.254            0.616                                                      G             86        0.82 (82%)      0.96 (96%)      0.0001^\*\*\*^
  GA              0.733            A                     14               0.18 (18%)       0.04 (4%)                                                                                                          
  AA              NA                                                                                                                                                                                          

HWE: Hardy Weinberg Equilibrium; NA: none of the subject had this genotype therefore t test was not available; ^\*^p \< 0.05; ^\*\*\*^p \< 0.0001

Allele and genotype frequencies of IL-8
---------------------------------------

In case of IL-8, the difference in genotype frequency for SNP [rs4073](http://www.ncbi.nlm.nih.gov/snp/?term=rs4073) between control and AMD patients was not significant (p\<0.4239; OR=1.301; CI 0.7347-2.3039). Allele frequency was not significantly different between control subjects and AMD patients (p\<0.2366; OR= 1.1635; CI 0.7703 -- 1.7575). For SNP [rs2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306), there was no statistically significant difference in the genotype frequency between AMD patients and control subjects (p\<0.0547; OR= 0.7101; CI 0.371 -- 1.3592). The frequency of allele T was significantly lower than allele C in AMD patients (p\<0.0001; OR= 0.5193; CI 0.3133-0.8608). For SNP [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543), the frequency of genotype TT was significantly higher in AMD patients compared to control subjects (p\<0.0371; OR= 0.8906; CI 0.5034-1.5756). The frequency of allele T was significantly higher in AMD patients compared to the control group (p\<0.0372; OR= 1.5529; CI 1.0257-2.3511). For SNP [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543), serum IL-8 levels were significantly higher in AMD patients with genotype TT compared to those with the CC or CT genotypes (p\<0.002; F= 6.80). No significant change in serum IL-8 levels was observed with respect to other SNPs ([Table 6](#t6){ref-type="table"}).

###### Genotype and allele frequencies in control and AMD patients for IL-8 SNPs.

  **Genotype**    **t test**       **Control (N=100)**   **AMD (N=90)**   **Alleles**     **Allele frequency reported in Pakistan (%)** \[[@r25]\]   **Control**   **AMD**   **p value**                     
  --------------- ---------------- --------------------- ---------------- --------------- ---------------------------------------------------------- ------------- --------- --------------- --------------- ----------------
  **rs4073**                                                                                                                                                                                                 
  TT              0.0001^\*\*\*^   0.368                 1.015            0.340           1.099                                                      T             64        0.625 (62.5%)   0.589 (58.9%)   0.2366
  AT              0.007^\*\*^      A                     36               0.375 (37.5%)   0.411 (41.1%)                                                                                                      
  AA              0.146                                                                                                                                                                                      
  **rs2227306**                                                                                                                                                                                              
  CC              0.0001^\*\*\*^   0.125                 2.148            0.951           0.050                                                      C             74        0.73 (73%)      0.84 (84%)      0.0001^\*\*\*^
  CT              0.0001^\*\*\*^   T                     26               0.27 (27%)      0.16 (16%)                                                                                                         
  TT              0.137                                                                                                                                                                                      
  **rs2227543**                                                                                                                                                                                              
  CC              0.0001^\*\*\*^   0.710                 0.495            0.002^\*\*^     6.80                                                       C             68        0.66 (66%)      0.555 (55.5%)   0.0372
  CT              0.0001^\*\*\*^   T                     32               0.34 (34%)      0.445 (45.5%)                                                                                                      
  TT              0.833                                                                                                                                                                                      

HWE: Hardy Weinberg Equilibrium; ^\*\*^p \< 0.01; ^\*\*\*^p \< 0.0001

Allele and genotype frequencies of VEGF
---------------------------------------

In the SNPs of VEGF, for [rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039), the genotype frequency in AMD patients was not significantly different compared to control subjects (p\<0.5124; OR= 0.899; CI 0.3544 -- 2.2807). There was no significant difference in allelic frequency between AMD patients and control subjects (p\<0.310; OR= 1.3956; CI 0.7329 -- 2.6577). For the gene variant [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), the genotype frequency between AMD patients and control subjects was not significantly different (p\<0.052; OR= 1.0114; CI 0.4079 -- 2.5078). The frequency of allele A was significantly higher in AMD patients compared to the control subjects (p\<0.0363; OR=1.5539; CI 1.0283-2.3482). Serum VEGF levels were significantly elevated in AMD patients with TT genotype for gene variant [rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039) compared to patients with CC or CT genotypes (p \< 0.038). For gene variant [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947), no significant change in serum VEGF concentration was observed between the control subjects and AMD patients with respect to the genotype ([Table 7](#t7){ref-type="table"}).

###### Genotype and allele frequencies in control and AMD patients for VEGF SNPs.

  **Genotype**    **t test**   **Control (N=100)**   **AMD (N=90)**   **Alleles**    **Allele frequency reported in Pakistan (%)** \[[@r25]\]   **Control**   **AMD**   **p value**                     
  --------------- ------------ --------------------- ---------------- -------------- ---------------------------------------------------------- ------------- --------- --------------- --------------- -------
  **rs3025039**                                                                                                                                                                                         
  CC              0.801        0.62                  0.481            0.038^\*^      3.441                                                      C             93        0.905 (90.5%)   0.872 (87.2%)   0.310
  CT              0.258        T                     7                0.095 (9.5%)   0.128 (12.8%)                                                                                                      
  TT              0.342                                                                                                                                                                                 
  **rs699947**                                                                                                                                                                                          
  CC              0.349        0.755                 0.283            0.938          0.396                                                      C             59        0.65 (65%)      0.54 (54%)      0.036
  CA              0.134        A                     41               0.35 (35%)     0.46 (46%)                                                                                                         
  AA              0.295                                                                                                                                                                                 

HWE: Hardy Weinberg Equilibrium; ^\*^p \< 0.05

Allele and genotype frequencies of CRP
--------------------------------------

In the gene variants of CRP, genotype frequency for SNP [rs1205](http://www.ncbi.nlm.nih.gov/snp/?term=rs1205) between control subjects and AMD patients was not significantly different (p\<0.6849; OR= 0.4779; CI 0.2398 -- 0.9524). No significant difference was found in allele frequency between AMD patients and control subjects (p\<0.342; OR= 1.107; CI 0.7376 -- 1.6614). For SNP [rs1130864](http://www.ncbi.nlm.nih.gov/snp/?term=rs1130864), there was no significant difference in genotype frequency between control subjects and AMD patients (p\<0.2411; OR= 1.0338; CI 0.5739 -- 1.8623). No significant difference was observed in allele frequency between controls subjects and AMD patients (p\<0.1560; OR= 1.4043; CI 0.8784 -- 2.2452). Likewise, no significant difference in serum CRP levels was observed between heterozygous or homozygous AMD patients (p\<0.618; F= 0.484) and control subjects for [rs1205](http://www.ncbi.nlm.nih.gov/snp/?term=rs1205) variant (p\<0.233; F=1.487). The CRP levels were not significantly different in heterozygous and homozygous individuals for gene variant [rs1130864](http://www.ncbi.nlm.nih.gov/snp/?term=rs1130864) in AMD patients (p\<0.534; F= 0.633) or healthy subjects (p\<0.171; F= 1.810; [Table 8](#t8){ref-type="table"}). For the above SNPs, allele frequencies reported previously \[[@r25]\] are also given in [Table 5](#t5){ref-type="table"}- [Table 8](#t8){ref-type="table"} for comparison purpose.

###### Genotype and allele frequencies in control and AMD patients for CRP SNPs.

  **Genotype**    **t test**       **Control (N=100)**   **AMD (N=90)**   **Alleles**    **Allele frequency reported in Pakistan (%)** \[[@r25]\]   **Control**   **AMD**   **p value**                  
  --------------- ---------------- --------------------- ---------------- -------------- ---------------------------------------------------------- ------------- --------- --------------- ------------ -------
  **rs1205**                                                                                                                                                                                             
  CC              0.856            0.233                 1.487            0.618          0.484                                                      C             75        0.575 (57.5%)   0.55 (55%)   0.342
  CT              0.0001^\*\*\*^   T                     25               0.425 (42.5)   0.45 (45%)                                                                                                      
  TT              0.123                                                                                                                                                                                  
  **rs1130864**                                                                                                                                                                                          
  AA              0.001^\*\*^      0.171                 1.810            0.534          0.633                                                      G             72        0.79 (79%)      0.72 (72%)   0.156
  AG              0.002^\*\*^      A                     28               0.21 (21%)     0.28 (28%)                                                                                                      
  GG              0.905                                                                                                                                                                                  

HWE: Hardy Weinberg Equilibrium; ^\*\*^p \< 0.01; ^\*\*\*^ p \< 0.0001

Discussion
==========

We found significant elevations in serum IL-6, IL-8, VEGF, and CRP levels in our AMD patients compared to healthy controls. Although, gene variants for IL-6, IL-8, and VEGF showed a significant association with the incidence of AMD, we did not observe any significant association between gene variants of CRP and the risk of AMD. This appears to coincide with the previously available epidemiologic, genetic, and pathologic data that support the view that inflammatory processes contribute to the initiation and progression of AMD \[[@r2],[@r3],[@r26]\]. Although plasma is preferable for estimating the above parameters \[[@r27]\], our patients presented and were diagnosed at different time intervals over the year and their samples were preserved at −20 °C. Consequently, sera were used for analyses instead of plasma.

There was no statistical difference in the ages of control subjects and AMD patients, supporting the comparability of the two groups. The unusual finding of our study is that the number of patients with wet-type AMD was greater than the dry type. This is in contrast to previous data showing that nearly four-fifths of all AMD cases present with dry AMD, which is characterized by early stage AMD without exudation or scarring of retinal tissue \[[@r26]\]. When compared with other populations of the world \[[@r28]\], this deviation in our sample population is possibly because dry AMD progresses slowly; patients perceive this visual loss as age related and so report it less frequently. It is expected that further large-scale studies on the general Pakistani population would confirm the proportion of patients with dry AMD.

In the present cohort of AMD patients, elevated levels of interleukins were indicative of the involvement of inflammatory processes in the pathology of AMD. As increased serum concentrations of pro-inflammatory cytokines, such as IL-6 and IL-8, are related to the production of reactive oxygen species, which further leads to the production of such cytokines, the positive feedback not only promotes inflammatory processes but also enhances vascularization, contributing ultimately to progression of the disease \[[@r29]\]. Our study revealed that patients with the CC genotype had lower serum IL-6 levels compared to those with the GG genotype. Allele C for SNP [rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795) has previously been associated with reduced IL-6 levels \[[@r30]\]. The functional C/G transversion in SNP [rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795) modulates binding of transcription factors, such as GATA1. The relationship between this genotype and IL-6 serum levels is complex due to the involvement of environmental interactions \[[@r31]\].

Importantly, our study implies that the presence of allele A for gene variant [rs1800797](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800797) appears to reduce the risk of AMD as its frequency was higher in control subjects than in AMD patients. This SNP is present in the promoter region of the IL-6 gene. Variation in this region is related to the functional alteration of the protein product that ultimately leads to occurrence of the disease \[[@r32]\]. Our study reveals that the presence of allele T in SNP [rs2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306) and allele C in SNP [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543) for the IL-8 gene is related to the risk of AMD as frequencies of these alleles were found to be higher in AMD patients compared to normal subjects. At the biochemical level, a significant elevation in serum IL-8 levels in AMD patients suggests that the SNPs under investigation are functional variants of the gene. A study in a Taiwan Chinese population examined 14 candidate SNPs of five interleukin genes and found that for SNP [2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306), allele T had a significant association with wet-type AMD, but for IL-6, no specific SNP was identified as a risk factor for AMD \[[@r5]\]. Thus, AMD seems to be the result of a linkage between many different gene loci related to the risk of disease.

We found serum VEGF concentration to be significantly increased in AMD patients compared to control subjects. Moreover, patients with wet-type AMD showed significantly higher VEGF levels compared to patients with dry-type AMD. VEGF is an important angiogenesis regulator that is overexpressed in retinal tissues of AMD patients. One of the key features of wet AMD is angiogenesis, which leads to neovascularization and ultimately blindness in the elderly population. Previous studies have provided evidence that VEGF is a major mediator of angiogenesis and vascular leakage in wet-type AMD \[[@r33]\].

Altered levels of VEGF gene expression due to polymorphism contributes to alteration in protein production \[[@r34]\]. In the same AMD patients, the frequency of allele A in VEGF gene variant [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) was found to be significantly higher compared to age-matched control subjects, while no significant change in allele or gene frequency was noticeable for gene variant [rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039). It is known that SNP [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) is present in the promoter region, while SNP [rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039) lies in the exon \[[@r35]\]. A significant association between AMD and allele T for SNP [rs3025039](http://www.ncbi.nlm.nih.gov/snp/?term=rs3025039) has been reported by Lin et al. \[[@r36]\] in the Chinese population, yet this association was not found in other studies performed on Caucasian \[[@r37]\] and Tunisian \[[@r38]\] populations.

We found that CRP levels were significantly elevated in AMD patients compared to control subjects. During chronic low-level inflammation, CRP levels are slightly raised as documented in a subset of aged individuals \[[@r39]\]. Meta-analysis has previously indicated a link between CRP and AMD, with elevated CRP levels being related to a twofold likelihood of late-onset AMD \[[@r40]\]; however, we could not find any association between serum CRP levels and its respective SNPs. One possibility is that CRP has some direct pathophysiologic role in AMD. This role is expected to be mediated through its capacity to induce complement activation via an unknown alternative pathway and contribute to tissue damage through several complement-mediated mechanisms \[[@r41]\]. In the present investigation, no significant change as related to CRP gene variants was observed. We studied SNPs [rs1205](http://www.ncbi.nlm.nih.gov/snp/?term=rs1205) and [rs1130864](http://www.ncbi.nlm.nih.gov/snp/?term=rs1130864), which are present in the untranslated region of the CRP gene. Although our study provides evidence that raised serum CRP levels are associated with AMD, this might not be solely due to genetic variation. Kim et al. \[[@r42]\] acquired similar results regarding the CRP gene in wet AMD patients. Genetic susceptibility of an individual in complex diseases such as AMD is the result of the cumulative effect of several predictive alleles studied with full haplotype information rather than a single allelic variation \[[@r43]\]. The polymorphisms in genes of several cytokines influence variation in cytokine production via gene transcription \[[@r44]\].

In conclusion, the present study provides evidence that elevated serum IL-6, IL-8, VEGF, and CRP levels are substantially increased in AMD. The IL-6 gene variants [rs1800795](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800795) and [rs1800797](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800797), IL-8 gene variants [rs2227306](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227306), [rs2227543](http://www.ncbi.nlm.nih.gov/snp/?term=rs2227543) and VEGF gene variant [rs699947](http://www.ncbi.nlm.nih.gov/snp/?term=rs699947) are involved in the AMD pathogenesis. However, the gene variants studied for CRP did not show any association with the disease. The data support the role of inflammation in AMD pathogenesis but do not provide specific insights as regards molecular mechanisms contributing to the disease.

The number of patients and controls in our study was relatively few due to very stringent inclusion criteria; thus, the findings do not represent the whole population of the country. Further functional and genomic studies are required to confirm our findings with studies performed on larger and more diverse samples from the same population so that involvement of inflammatory and angiogenic factors in the pathogenesis of AMD can be delineated.
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